1. Home
  2. UFPT vs MESO Comparison

UFPT vs MESO Comparison

Compare UFPT & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UFP Technologies Inc.

UFPT

UFP Technologies Inc.

N/A

Current Price

$295.98

Market Cap

1.8B

Sector

Health Care

ML Signal

N/A

Logo Mesoblast Limited

MESO

Mesoblast Limited

N/A

Current Price

$14.29

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UFPT
MESO
Founded
1963
2004
Country
United States
Australia
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
2.0B
IPO Year
1996
2005

Fundamental Metrics

Financial Performance
Metric
UFPT
MESO
Price
$295.98
$14.29
Analyst Decision
Buy
Buy
Analyst Count
4
3
Target Price
★ $355.00
$37.00
AVG Volume (30 Days)
74.7K
★ 152.2K
Earning Date
11-02-2026
08-26-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 15.44
N/A
EPS
★ 4.92
N/A
Revenue
★ $602,797,000.00
N/A
Revenue This Year
$9.23
$58.89
Revenue Next Year
$5.41
$58.93
P/E Ratio
$59.98
★ N/A
Revenue Growth
★ 19.50
N/A
52 Week Low
$173.86
$13.05
52 Week High
$338.71
$21.50

Technical Indicators

Market Signals
Indicator
UFPT
MESO
Relative Strength Index (RSI) 55.64 40.06
Support Level $224.12 $14.18
Resistance Level $330.51 $16.06
Average True Range (ATR) 7.18 0.40
MACD 1.79 -0.08
Stochastic Oscillator 77.98 9.78

Price Performance

Historical Comparison
UFPT
MESO

About UFPT UFP Technologies Inc.

UFP Technologies Inc is a contract development and manufacturing organization that specializes in single-use and single-patient medical devices. The company manufactures its products by converting raw materials using laminating, molding, radio frequency, and impulse welding, and fabricating manufacturing techniques. It is an important link in the medical device supply chain and a valued outsource partner to many of the top medical device manufacturers in the world. The company's single-use and single-patient devices and components are used in a wide range of medical devices, disposable wound care products, infection prevention, minimally invasive surgery, wearables, orthopedic soft goods, and orthopedic implant packaging.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.

Share on Social Networks: